Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) is expected to be releasing its earnings data before the market opens on Wednesday, March 26th. Analysts expect Mereo BioPharma Group to post earnings of $0.02 per share for the quarter.
Mereo BioPharma Group Stock Performance
MREO stock traded down $0.18 during mid-day trading on Friday, reaching $2.38. 1,043,861 shares of the company's stock were exchanged, compared to its average volume of 1,006,758. Mereo BioPharma Group has a 12-month low of $2.25 and a 12-month high of $5.02. The stock's 50 day moving average is $2.79 and its 200 day moving average is $3.56.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on MREO. Jefferies Financial Group assumed coverage on Mereo BioPharma Group in a research report on Friday, December 6th. They set a "buy" rating and a $7.00 target price on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $7.00 target price on shares of Mereo BioPharma Group in a research report on Tuesday. Lifesci Capital began coverage on shares of Mereo BioPharma Group in a research report on Tuesday, December 24th. They set an "outperform" rating and a $10.00 price target for the company. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $7.00 price objective on shares of Mereo BioPharma Group in a report on Monday, January 13th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Mereo BioPharma Group currently has a consensus rating of "Buy" and an average price target of $7.83.
Get Our Latest Report on MREO
Mereo BioPharma Group Company Profile
(
Get Free Report)
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.
Featured Articles
Before you consider Mereo BioPharma Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mereo BioPharma Group wasn't on the list.
While Mereo BioPharma Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
